Real-world experiences with CGRP antagonists in migraine
Specialists have reported new data on the real-world use of calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) therapies, showing that reductions in headache frequency are achieved that are similar to those seen in clinical trials.